Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy

NCT ID: NCT05700097

Last Updated: 2023-01-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 240 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-30
• Study Completion Date: 2023-12-31

Brief Summary

To assess the Efficacy and Safety of Dengzhanxixin Injection in Patients With Acute Ischemic Stroke Receiving Reperfusion Therapy.

Detailed Description

To evaluate the safety and efficacy of Dengzhanxixin at different doses of 80ml/day, 40 ml/day, or placebo within 24 hours after the onset of ischemic stroke. The primary objective of this study is the proportion of subjects with excellent outcomes defined as mRS (0-1) among the three treatment groups at 90 days.

Conditions

Acute Ischemic Stroke

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Low Dose Arm

Dengzhanxixin injection 40ml/day, placebo 40ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day; placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day.

Group Type: EXPERIMENTAL

Dengzhanxixin Injection

Intervention Type: DRUG

Experimental arms for low, and high dose for the standard protocol

High Dose Arm

Dengzhanxixin injection 80ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.

Group Type: EXPERIMENTAL

Dengzhanxixin Injection

Intervention Type: DRUG

Experimental arms for low, and high dose for the standard protocol

Placebo Arm

Placebo injection 80ml/day. Placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.

Group Type: PLACEBO_COMPARATOR

Placebo injection

Intervention Type: DRUG

placebo control arm for the standard protocol

Interventions

Dengzhanxixin Injection

Experimental arms for low, and high dose for the standard protocol

Intervention Type: DRUG

Placebo injection

placebo control arm for the standard protocol

Intervention Type: DRUG

Other Intervention Names

Dengzhanxixin Zhusheye; Placebo

Eligibility Criteria

Inclusion Criteria

• More than or equal to 18 years old and less than 80 years old;
• Acute ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) of the head;
• Stroke onset within 24 hours and can be treated with study drug within 24 hours of symptoms onset；
• The patient has received or is planning to receive vascular reperfusion therapy after onset；
• Baseline NIHSS score is ≥4 and ≤26.
• mRS ≤1 prior onset.
• Informed consent signed.

Exclusion Criteria

• Intracranial hemorrhage: cerebral hemorrhage, subarachnoid hemorrhage, etc.;
• The acute infarcts lesion Involvement of more than one-third of middle cerebral artery (MCA) territory on initial brain imaging;
• Rapidly improving symptoms at the discretion of the investigator;
• Patients who have taken Dengzhanxixin Injection，edaravone or other brain protective drugs after onset ;
• History of intracranial hemorrhage；
• History of severe head trauma, stroke or myocardial infarction in past 3 months;
• Diagnosised intracranial tumor and giant intracranial aneurysm；
• Diagnosised aortic arch dissection；
• Undergoing major surgery within 2 weeks prior to screening; or intracranial or intraspinal surgery within 3 months prior to screening;
• Currently accompanied by active visceral bleeding; or arterial puncture at a site that is not easy to compress hemostasis within 1 week before screening; or gastrointestinal or urinary system bleeding occurred within 3 weeks before screening;
• Those with acute bleeding tendency, including: platelet count <100×109/L, combined with hemophilia, etc.; or those with partially activated thrombin time greater than 3 times the upper limit of normal;
• Oral anticoagulants, and international normalized ratio>1.7 or prothrombin time>15s;
• Diagnosed primary liver and kidney disease, AST or ALT (>2 times the ULN), serum creatinine >2.0mg/dL or >176.8µmol/L;
• Persistent blood pressure elevation ( systolic ≥180 mmHg or diastolic ≥100 mmHg ), despite blood pressure lowering treatment;
• Those with a history of epilepsy or epilepsy-like symptoms at the onset of stroke;
• Complete atrioventricular block; or according to the New York Heart Association (NYHA) cardiac function class II or above; or have been hospitalized due to congestive heart failure within 6 months before screening;
• Pregnant women, nursing mothers, or reluctant to agree taking effective contraceptive measures during the period of trial subjects;
• Those who have other neurological diseases or disabilities or mental diseases, which may affect the efficacy evaluation of this study as judged by the investigator;
• Those with a history of malignant tumor within 5 years before screening (if the patient has basal cell carcinoma of the skin or carcinoma in situ of the cervix and has been cured, he/she can participate in this study);
• Those who participated in other drug/device clinical studies and used the experimental drug/device within 3 months before screening;
• Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study。

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Tiantan Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yongjun Wang, M.D.

Role: PRINCIPAL_INVESTIGATOR

Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Locations

Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

NCRC-2022-02

Identifier Type: -

Identifier Source: org_study_id